Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF (HFpEF-PRoF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02589977|
Recruitment Status : Completed
First Posted : October 28, 2015
Last Update Posted : April 10, 2020
Marvin W. Kronenberg, M.D.
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
Marvin W. Kronenberg, M.D., Vanderbilt University Medical Center
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||January 21, 2020|
|Actual Study Completion Date :||January 21, 2020|
Publications of Results:
Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013 Dec;19(12):802-10. doi: 10.1016/j.cardfail.2013.10.010. Epub 2013 Oct 29.